Developing Collagen Sponge to Stop Severe Bleeding

Researchers at Penza State University in Russia have developed an experimental collagen sponge engineered to halt bleeding, inhibit fibrinolysis, and eradicate harmful bacteria efficiently. Information released by the Russian Ministry of Science and Higher Education press office indicates that the innovative device utilizes a lightweight, highly porous three-dimensional collagen scaffold. This specialized architecture enables rapid fluid absorption while collagen actively triggers the body natural coagulation cascade, creating ideal conditions for prompt blood clot generation. The sponge is also infused with aminocaproic acid to suppress fibrinolysis by preventing plasminogen activation, which preserves and stabilizes the clot during initial formation. Extended local antimicrobial coverage is achieved through incorporated vancomycin and ciprofloxacin compounds, preventing infection over sustained periods. Researcher Natalia Starodubova pointed out that the critical objective involves not only rapid hemostasis but also securing clot integrity against premature breakdown and minimizing microbial contamination. She emphasized that existing commercial hemostatic products fail to combine all these essential features optimally. The fabrication process follows sequential stages involving collagen matrix synthesis, incorporation of active pharmaceutical agents during raw material swelling, subsequent freezing, and final lyophilization, ensuring controlled release of active substances. Laboratory evaluations validated the biomaterial efficiency through meticulous structural analysis, absorption dynamics, antimicrobial testing, and erythrocyte biocompatibility assays. Current scientific efforts are dedicated to standardizing mass production techniques and optimizing the formulation for broader clinical applications.